APA (7th ed.) Citation

Harrison, S. J., Richardson, P. G., Alegre, A., Simpson, D., Wang, M. C., Spencer, A., . . . Attal, M. (2019). Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis. Clinical lymphoma, myeloma & leukemia, 19, e33. https://doi.org/10.1016/j.clml.2019.09.049

Chicago Style (17th ed.) Citation

Harrison, Simon J., et al. "Efficacy of Isatuximab/pomalidomide/dexamethasone in Relapsed/refractory Multiple Myeloma: ICARIA-MM High-risk Cytogenetics Subgroup Analysis." Clinical Lymphoma, Myeloma & Leukemia 19 (2019): e33. https://doi.org/10.1016/j.clml.2019.09.049.

MLA (9th ed.) Citation

Harrison, Simon J., et al. "Efficacy of Isatuximab/pomalidomide/dexamethasone in Relapsed/refractory Multiple Myeloma: ICARIA-MM High-risk Cytogenetics Subgroup Analysis." Clinical Lymphoma, Myeloma & Leukemia, vol. 19, 2019, p. e33, https://doi.org/10.1016/j.clml.2019.09.049.